Endocrine Regulation of Lipolysis in Obesity and Diabetes (ERLO)

Atrial Natriuretic Peptide (ANP)-Induced Lipid Mobilization Regulation in Different Adipose Tissue Depots of Obese Subjects

Adipose tissue (AT) dysfunction is a commonly observed feature of metabolic dysfunction in obesity and diabetes. An important characteristic when examining AT function is the capacity to break down stored lipids (i.e. lipolysis) and its regulation. In the present study, the aim was to investigate whether atrial natriuretic peptide-mediated lipolysis is altered in different adipose tissue depots (subcutaneous and visceral adipose tissue) of obese subjects with or without type 2 diabetes, compared to age-matched lean men. Eventually, the knowledge gained from this research will contribute to a better understanding of the present adipose tissue dysfunction and to the optimization of exercise programs for people with obesity and diabetes.

Study Overview

• Status: Completed
• Conditions: Obesity; Diabetes
• Intervention / Treatment: Other: adipose tissue sampling

• Study Type: Interventional
• Enrollment (Actual): 55
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Diepenbeek, Belgium, B-3590
    • Hasselt University
  • Genk, Belgium, B-3600
    • Ziekenhuis Oost-Limburg
  • Hasselt, Belgium, B-3500
    • Jessa Ziekenhuis
• Netherlands
  • Maastricht, Netherlands
    • Maastricht University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Lean group: BMI < 25 kg/m², insulin sensitive (HOMA-Insuline Resistance (IR) < 2.3), age 40-65
• Obese groups: BMI > 30 kg/m², presence or absence of type 2 diabetes based on use of glucose lowering medication or HbA1c > 6.5%, age 40-65

Exclusion Criteria:

• presence of a history of heart, lung or kidney disease and/or presence of endocrine anomalies. Use of beta-blockade medication.

Study Plan

How is the study designed?

Design Details

• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: lean men	Other: adipose tissue sampling; adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
Other: Obese men without type 2 diabetes	Other: adipose tissue sampling; adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
Other: Obese men with type 2 diabetes	Other: adipose tissue sampling; adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Glycerol release by mature adipocytes, isolated from subcutaneous and visceral adipose tissue, upon stimulation with isoprenalin or ANP (ex vivo)	Investigation of concentration effect of ISO/ANP on lipolysis (glycerol release) by mature adipocytes isolated from adipose tissue biopsies, glycerol release is measured in the incubation medium following a 3 hour incubation period. Measured for adipose tissue (subcutaneous and visceral adipose tissue) of both lean and obese subjects	day 1
ANP receptor expression profiles on mRNA and protein level in both adipose tissue depots for both lean and obese subjects.	Receptor expression determination in order to clarify the underlying mechanism responsible for possible differences in lipolytic responses.	day 1
Adipose tissue inflammation	Adipose tissue inflammation (by means of FACS analysis) and its relation to insulin sensitivity and adipose tissue function in lean, obese and obese diabetics subjects.	day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Body composition	Body composition (body fath percentage), measured by BIA	day 1
BMI (kg/m²)		day 1
body height (m)		day 1
weight (kg)		day 1
hip circumference (cm)		Day 1
waist (cm)		Day 1
blood glucose		day 1
blood insuline		day 1
blood FFA		day 1
blood triglycerides		day 1
blood glycated hemoglobin		day 1
blood ANP	fasting blood sample to determine blood glucose, insulin, FFA, , glycated hemoglobin and ANP	day 1
blood pressure (mmHg)		Day 1
Concomitant medication		Day 1

Collaborators and Investigators

• Sponsor: Hasselt University
• Collaborators: Jessa Hospital
• Investigators: Principal Investigator: Ellen Blaak, prof. dr., Maastricht University; Study Chair: Kenneth Verboven, drs., Hasselt University

Study record dates

Study Major Dates

• Study Start: May 1, 2013
• Primary Completion (Actual): April 1, 2015
• Study Completion (Actual): April 1, 2015

Study Registration Dates

• First Submitted: October 16, 2015
• First Submitted That Met QC Criteria: November 4, 2015
• First Posted (Estimate): November 6, 2015

Study Record Updates

• Last Update Posted (Estimate): November 18, 2016
• Last Update Submitted That Met QC Criteria: November 16, 2016
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Overweight; Body Weight; Obesity
• Other Study ID Numbers: 14.17/REVA14.02